|The VEGFR-1/Flt-1 flt1 (Catalog #MBS692479) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Mouse Anti-Hu/Mo VEGFR-1/Flt-1, Antagonistic reacts with Human, Mouse and may cross-react with other species as described in the data sheet. MyBioSource\'s VEGFR-1/Flt-1 can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), Blocking. Researchers should empirically determine the suitability of the VEGFR-1/Flt-1 flt1 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The VEGFR-1/Flt-1 flt1 product has the following accession number(s) (GI #229892220) (NCBI Accession #NP_001153392.1) (Uniprot Accession #P17948). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVE supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The antibody will bind near the ligand binding site of the receptor and has antagonistic activity by blocking the binding of natural ligands.
Reconstitution: Reconstitute the antibody with 400 ul sterile PBS and the final concentration is 500 ug/ml. Antibody Generation: This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse immunized with purified extracellular domain of recombinant human VEGFR1. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing VEGFR-1/Flt-1 are readily searchable from our website. Different antibodies against the same target such as VEGFR-1/Flt-1 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. VEGFR-1/Flt-1 also interacts with the following gene(s): EPAS1, HIF1A, NRP1, NRP2, PGF, SHC1, VEGFA, VEGFB.